Case Report

Teratoma with Malignant Transformation: A Case Report with Pathological, Cytogenetic, and Immunohistochemistry Analysis

Jue Wang¹ and Syed A. Jaffar Kazmi²

¹Department of Internal Medicine, Section of Oncology–Hematology, University of Nebraska Medical Center, Omaha, NE 68198–7680, USA
²Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198–6495, USA

Correspondence should be addressed to Jue Wang, juewang@unmc.edu

Received 2 March 2011; Accepted 20 April 2011

1. Introduction

Teratoma with malignant transformation (TMT) is germ cell tumor (GCT) which underwent malignant transformation of a somatic teratomatous component to histology that is identical to a somatic malignancy (e.g., carcinoma or sarcoma) [1–8]. TMTs are rare and most commonly encountered in adult patients with GCT. The most frequent malignant components associated with testicular GCT are sarcomas [1, 4]. TMTs are usually metastatic at presentation, have a high recurrence rate, and are more aggressive than teratomas without malignant transformation [5–8]. The prognosis is especially poor for mediastinal TMTs and for those with neural or rhabdomyosarcomatous differentiation [1, 2, 7]. Surgical resection is the mainstay of therapy for localized disease, because TMTs are considered to be resistant to radiation and systemic chemotherapy [8–11]. Effective therapeutic strategies targeted to TMT are needed. A case of TMT successfully treated according to a combined modality is presented here along with a description of immunohistochemistry, molecular cytogenetics assays results.

2. Case Report

The patient is a 44-year-old Caucasian male who presented with one-month history of weight loss, cough, pleuritic chest pain and dyspnea. Computed tomography of the chest revealed two right lung masses that measured 6.8 and 10.5 cm (Figure 1). Fine needle aspiration biopsy showed high-grade sarcomatoid malignancy which consistent with embryonal rhabdomyosarcoma. Upon further investigation a right testicular mass was noted. However α-fetoprotein, β-human chorionic gonadotropin, carcinoembryonic antigen (CEA), and lactate dehydrogenase assays were normal. A right orchiectomy revealed a malignant teratoma. The patient was subsequently transferred to our hospital for
chest pain and hemoptysis. A bronchoscopy was performed which did not show any active bleeding, a suspicious endobronchial lesion was biopsied that showed no evidence of malignancy. PET scan showed increase uptake in both pulmonary lesions (Figure 2). The patient subsequently had right pneumonectomy.

The patient developed a 4 cm liver metastasis two months after pneumonectomy. The patient was subsequently treated according to the arm II of ARST0531 [12] protocol (A Randomized Study of Vincristine, Dactinomycin, and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma; VAC alternating with vincristine and irinotecan hydrochloride: vincristine IV over 1 minute on day 1 of weeks 1–13, 16, 17, 19, 20, 22–26, 28, 31–34, 37, 38, and 40; dactinomycin IV over 1–5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1, 10, 13, 22, 28, 34, and 40; irinotecan hydrochloride IV over 1 hour on days 1–5 of weeks 4, 7, 16, 19, 25, 31, and 37). He had a complete response of his liver lesion and remains disease-free at 16 months of follow-up after initial diagnosis.

3. Pathologic and Cytogenetics Findings

Pathologic examination of the right pneumonectomy specimen revealed two masses measuring $10.1 \times 9.8 \times 7.4 \text{ cm}$ and $10.9 \times 9.4 \times 8.1 \text{ cm}$, grossly abutting the visceral pleura with a thickened fibrotic capsule. Both of the tumor masses were firm rubbery with homogenous tan-white fibrous fleshy
cut surfaces. The tumor obliterated most of the normal lung parenchyma with only scattered residual entrapped alveoli.

Microscopically, the tumor was composed predominantly of pleomorphic spindle to round cells with scant cytoplasm and round-to-irregular hyperchromatic nuclei (Figure 3(a)). Rhabdoid cells with abundant eosinophilic cytoplasm and eccentric nuclei, were abundant (Figure 3(a)). Rare scattered cells with more terminal differentiation (strap cell) were also noted. Tumor also demonstrated a focal area of chondrosarcomatous differentiation consisting of round to spindle cells with pericellular clearing; foci of hyaline cartilage were also noted (Figure 3(b)). The tumor demonstrated a brisk mitotic activity and multifocal necrosis. Immunohistochemistry showed that the tumor cells were positive for desmin (Figure 3(c)), myogenin (Figure 3(d)), MyoD1, and CD99, and negative for pancytokeratin, CAM5.2, actin, and OSCAR (not shown). The final diagnosis was metastatic embryonal rhabdomyosarcoma with a focal area of chondrosarcoma. Both tumor’s masses show the same histology. No GCT was identified. Surgical margins were negative. Multiple lymph nodes were harvested without evidence of malignant involvement.

Pathologic examination of the testicular mass showed a malignant germ cell tumor composed of teratoma. There was no evidence of immature or somatic type malignant components upon extensive sampling. Fluorescence in situ hybridization (FISH) studies were performed on paraffin sections from lung mass utilizing Homebrew 12p13.2 DNA probe with CEP 12 at the University of Nebraska Medical Center genetics laboratory. Molecular cytogenetic analysis revealed a normal male 46, XY karyotype with presence of i(12p).

4. Tumor Profiling by Immunohistochemistry Analysis

In order to identify potential target and biomarkers and therapies associated with clinical benefit, further immunohistochemistry and molecular studies were performed. As demonstrated by Figure 4, Immunohistochemistry study showed high expression of the following proteins: Topoisomerase-II alpha (Topo IIa; 2+, 30%), Topoisomerase I (Topo I; 2+, 10%). In addition, Multidrug resistance-related protein-1 (MRP1) (1+, 60%), O6-methylguanine-DNA methyltransferase, (MGMT; 1+, 90%), breast cancer resistance protein
Figure 4: Immunohistochemistry findings of the pulmonary tumor. (a) Rhabdomyoblasts with Topo 2a, (b) Topo I.

(BCRP; 2+, 90%), excision repair cross-complementation group 1 (ERCC1; 1+, 10%), ribonucleoside-diphosphate reductase large subunit (RRM1; 2+, 80%), and thymidylate synthase (TS; 2+, 50%).

5. Discussion

Somatic-type malignancies develop in 3% to 6% of GCT with teratomatous differentiation [1, 4]. It was postulated that they develop from either malignant transformation (MT) of pre-existing teratomatous elements or by differentiation of totipotential germ cells with concomitant MT. The most frequent somatic malignancies associated with GCT are sarcomas, rhabdomyosarcoma being the most common subtype [1, 2]. Up to 80% of patients with TMT present with metastases have a high recurrence rate and poor prognosis whereas others present with unresectable disease [5].

A notable feature of current case is the fact that no sarcomatous component was identified in the testicular mass and no germ cell element was identified in the resected pulmonary tumor. Although extensive histopathologic evaluation was undertaken, sampling error cannot be completely excluded. The presence of two different types of sarcomas (i.e., rhabdomyosarcoma and chondrosarcoma) in the same metastasis favor a GCT origin. The GCT origin of rhabdomyosarcoma in this case is also strongly supported by the presence of i(12p). Chromosomal abnormalities in these TMTs include i(12p), reflecting germ cell tumor clonality, as well as chromosomal abnormalities associated with the transformed histology. Only a few cytogenetic studies have been performed on transformed tumors [13]. Motzer et al. reported i(12p) in 10 of 12 transformed tumors studied including adenocarcinoma, peripheral primitive neuroectodermal tumor, and rhabdomyosarcoma [1].

The treatment of TMTs remains a challenge. TMTs have traditionally been thought to be unresponsive to chemotherapy, including cisplatin-containing chemotherapy regimens [10]. Patients who had complete resection of TMTs had significantly better overall survival, and the prognosis for patients with metastatic disease was very poor [3]. Recent reports indicate that chemotherapy directed against transformed component may achieve better results [11]. There have been only a few reports of successful treatment of metastatic TMTs with chemotherapy with long-term survival to doxorubicin-based chemotherapy [10, 11].

Our finding of overexpression of several drug-resistant genes is in line with the clinical observations of lack of response to chemotherapy in these tumors. High expression of MRP1 has been associated with lack of response to etoposide and vincristine [14]. High expression of BCRP has been associated with shorter progression-free (PFS) and overall survival (OS), when treated with platinum-based combination chemotherapy [15, 16]. In addition, genes encode enzyme that catalyzes the biosynthesis of nucleic acid (RRM1), and gene encodes macromolecular target of a cytotoxic drug (MGMT, TS) also over expressed. High expression of RRM1 expression was associated with lack of response to gemcitabine and poor outcome [17]. High expression of MGMT has been linked with resistance to temozolomide-based therapy [18]. High TS has been associated with lack of response to fluoropyrimidine [19].

The outcome for patients with metastatic RMS has remained approximately 30% survival for several decades. It has long been recognized that interpatient variability in response to chemotherapy is associated with different outcomes. The complete clinical response with irinotecan-based regimen in this case is interesting. The overexpression of Topo IIa, Topo I in tumor suggested they are attractive targets for novel therapy. Topo I and IIa are enzymes that alter the supercoiling of double-stranded DNA. They act by transiently cutting one or both strands of the DNA. Topo I cuts one strand whereas topoisomerase II cuts both strands of the DNA to relax the coil and extend the DNA molecule [20]. High expression of Topo I has been associated with response to first-line chemotherapy containing irinotecan, a Topo I inhibitor while overexpression of Topo IIa conferred higher probability of response to doxorubicin, a DNA intercalating agent [21, 22].

The advent of the human genome sequencing project and the development of high-throughput technologies, including
microarrays, have allowed oncologists to explore the possibility of using gene expression profiles to predict chemotherapeutic drug sensitivity or resistance before treatment, and thereby select the best possible therapies while decreasing the risk of toxicities for the patients. In order to achieve this goal, an international virtual sample bank of this rare tumor is necessary. The Sarcoma Foundation of American Patient Registry and ongoing international efforts to evaluate high-dose chemotherapy in the salvage setting (TIGER protocol) may provide a good opportunity to collect such rare cases.

In conclusion, we report a rare case of malignant testicular teratoma with metastatic TMT/ERMS. Our findings of overexpression of several drug-resistant genes is consistent with the previous clinical observations of poor chemotherapy response in these tumors. The usefulness of biomarkers for chemotherapy selection should be further tested in a future study.

References

[1] R. J. Motzer, A. Amsterdam, V. Prieto et al., “Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors,” Journal of Urology, vol. 159, no. 1, pp. 133–138, 1998.
[2] C. V. Comiter, A. S. Kibel, J. P. Richie, M. R. Nucci, and A. A. Renshaw, “Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases,” Journal of Urology, vol. 159, no. 3, pp. 859–863, 1998.
[3] A. Athanasiou, D. Vanel, O. El Mesbahi, C. Theodore, and K. Fizazi, “Non-germ cell tumours arising in germ cell tumours (teratoma with malignant transformation) in men: CT and MR findings,” European Journal of Radiology, vol. 69, no. 2, pp. 230–235, 2009.
[4] T. Ahmed, G. J. Bosl, and S. I. Hajdu, “Teratoma with malignant transformation in germ cell tumors in men,” Cancer, vol. 56, no. 4, pp. 860–863, 1985.
[5] R. Corbett, R. Carter, D. MacVicar, A. Horwich, and R. Pinkerton, “Embryonal rhabdomyosarcoma arising in a germ cell tumour,” Medical and Pediatric Oncology, vol. 23, no. 6, pp. 497–502, 1994.
[6] C. Rebischung, P. H. Cottu, A. Daban et al., “Germ-cell tumours containing non-germ-cell neoplasms: teratoma with malignant transformation,” Urologic Oncology, vol. 6, no. 6, pp. 239–242, 2001.
[7] T. M. Ulbright, P. J. Loehrer, L. M. Roth et al., “The development of non-germ-cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases,” Cancer, vol. 54, no. 9, pp. 1824–1833, 1984.
[8] J. S. Little Jr., R. S. Foster, T. M. Ulbright et al., “Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy,” Journal of Urology, vol. 152, no. 4, pp. 1144–1149, 1994.
[9] O. El Mesbahi, M. J. Terrier-Lacombe, C. Rebischung, C. Theodore, D. Vanel, and K. Fizazi, “Chemotherapy in patients with teratoma with malignant transformation,” European Urology, vol. 51, no. 5, pp. 1306–1311, 2007.
[10] A. C. Donadio, R. J. Motzer, D. F. Bajorin et al., “Chemotherapy for teratoma with malignant transformation,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4285–4291, 2003.
[11] A. Korfel, L. Fischer, H. D. Foss, H. C. Koch, and E. Thiel, “Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature,” Bone Marrow Transplantation, vol. 28, no. 8, pp. 787–789, 2001.
[12] http://www.clinicaltrials.gov/ct2/show/NCT00354744?term=ARST0531&rank=1.
[13] K. M. Kernek, M. Brunelli, T. M. Ulbright et al., “Fluorescence in situ hybridization analysis of chromosome 12p in paraffin-embedded tissue is useful for establishing germ cell origin of metastatic tumors,” Modern Pathology, vol. 17, no. 11, pp. 1309–1313, 2004.
[14] J. J. Yeh, N. Y. Hsu, W. H. Hsu, C. H. Tsai, C. C. Lin, and J. A. Liang, “Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer,” Lung, vol. 183, no. 3, pp. 177–183, 2005.
[15] K. Yoh, G. Ish II, T. Yokose et al., “Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer,” Clinical Cancer Research, vol. 10, no. 5, pp. 1691–1697, 2004.
[16] J. E. Diestra, E. Condom, X. G. del Muro et al., “Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications,” Journal of Urology, vol. 170, no. 4, part 1, pp. 1383–1387, 2003.
[17] G. Bepler, I. Kusmartseva, S. Sharma et al., “RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4731–4737, 2006.
[18] T. Fukushima, H. Takeshima, and H. Kataoka, “Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT,” Anticancer Research, vol. 29, no. 11, pp. 4845–4854, 2009.
[19] A. Paradiso, G. Simone, S. Petroni et al., “Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients,” British Journal of Cancer, vol. 82, no. 3, pp. 560–567, 2000.
[20] M. L. Rothenberg, “Topoisomerase I inhibitors: review and update,” Annals of Oncology, vol. 8, no. 9, pp. 837–855, 1997.
[21] M. S. Braun, S. D. Richman, P. Quirke et al., “Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial,” Journal of Clinical Oncology, vol. 26, no. 26, p. 4363, 2008.
[22] V. Durbecq, M. Paemans, F. Cardoso et al., “Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel,” Molecular Cancer Therapeutics, vol. 3, no. 10, pp. 1207–1214, 2004.